Altitude Life Science Ventures
Philosophy is to focus on life science markets with strong demand and growth potential, and then back the highest-quality entrepreneurs in
Business Model: B2B
Revenue: $0
Employees: 0-0
Rankings
Industries / Tags:
Detailed Altitude Life Science Ventures Information
Geographic Data
Address:
City: Kirkland
State: WA
Zip: 98033
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$0
Social
Crunchbase
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
Philosophy is to focus on life science markets with strong demand and growth potential, and then back the highest-quality entrepreneurs in those markets to build defensible, strong, and long-term businesses. build portfolio among attractive life science sectors in a manner that balances risk while maximizing potential synergies and ultimate returns. Our focus is on opportunities in biotechnology, medical devices, and diagnostics, but we are continually responsive to the best areas for investing in order to adapt to changing market conditions. Invest in companies that: * are pursuing substantial and growing market opportunities * possess a unique and proprietary technology, with a clear competitive advantage * are early-stage opportunities * have or will attract strong management * have a strong investment syndicate * offer a defined path to liquidity
Contact Phone:
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 6/2019 | Encoded Therapeutics | Series C | 104M |
| 6/2010 | Constellation Pharmaceuticals | Series B | 22.3M |
| 6/2011 | Constellation Pharmaceuticals | Series B | 15M |
| 7/2021 | Ring Therapeutics | Series B | 117M |
| 4/2017 | Sienna Biopharmaceuticals | Series B | 0 |
| 7/2018 | Omniome | Series B | 0 |
| 11/2009 | Cambrios Technologies | Series D | 14.5M |
| 3/2020 | Cero Therapeutics | Series A | 0 |
| 3/2018 | UNITY Biotechnology | Series C | 55M |
| 1/2017 | Vir Biotechnology | Venture Round | 150M |
| 10/2022 | Neumora Therapeutics | Series B | 0 |
| 11/2021 | Generate Biomedicines | Series B | 0 |
| 8/2009 | Constellation Pharmaceuticals | Series A | 17.2M |
| 10/2016 | BlackThorn Therapeutics | Series A | 40M |
| 5/2008 | Kythera Biopharmaceuticals | Series C | 0 |
| 7/2006 | Kythera Biopharmaceuticals | Series B | 30M |
| 7/2012 | Siluria Technologies | Series C | 30M |
| 1/2020 | Omniome | Series C | 60M |
| 10/2019 | Nuvation Bio | Series A | 275M |
| 1/2021 | Tessera Therapeutics | Series B | 0 |
| 4/2022 | Ansa Biotechnologies | Series A | 68M |
| 6/2015 | Pulmatrix | Post-IPO Equity | 10M |
| 3/2013 | Receptos | Series B | 30M |
| 1/2021 | Dice Therapeutics | Series C | 80M |
| 12/2015 | Effector Therapeutics | Series B | 40M |
| 8/2018 | Millendo Therapeutics | Venture Round | 30M |
| 1/2016 | Millendo Therapeutics | Series B | 0 |
| 8/2021 | Effector Therapeutics | Post-IPO Equity | 0 |
| 7/2017 | Effector Therapeutics | Series C | 38.6M |
| 10/2021 | Neumora Therapeutics | Series A | 0 |
| 10/2010 | Siluria Technologies | Series A | 13.3M |
| 4/2022 | Tessera Therapeutics | Series C | 0 |
| 4/2019 | Vividion Therapeutics | Series B | 82M |
| 6/2020 | Sana Biotechnology | Series A | 700M |
| 6/2019 | BlackThorn Therapeutics | Series B | 76M |
| 10/2021 | Mozart Therapeutics | Series A | 0 |
| 4/2016 | Sienna Biopharmaceuticals | Series A | 34M |
| 3/2019 | Beam Therapeutics | Series B | 135M |
| 9/2011 | Siluria Technologies | Series B | 20M |
| 7/2009 | Limerick BioPharma | Series C | 15M |
| 6/2008 | Limerick BioPharma | Venture Round | 15.2M |
| 5/2007 | Arete Therapeutics | Series A | 35M |
| 9/2011 | Kythera Biopharmaceuticals | Series D | 0 |
| 4/2022 | Tessera Therapeutics | Series C | 0 |
| 4/2022 | Ansa Biotechnologies | Series A | 0 |
| 11/2021 | Generate Biomedicines | Series B | 0 |
| 10/2021 | Mozart Therapeutics | Series A | 0 |
| 10/2021 | Neumora Therapeutics | Series A | 0 |
| 8/2021 | Effector Therapeutics | Post-IPO Equity | 0 |
| 7/2021 | Ring Therapeutics | Series B | 0 |
| 1/2021 | Tessera Therapeutics | Series B | 0 |
| 1/2021 | Dice Therapeutics | Series C | 0 |
| 6/2020 | Sana Biotechnology | Series A | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
